Company intelligence / Profile preview

Warrick Pharmaceuticals

Kenilworth, New Jersey, United States

Ownership: Private
Development stage: Other

Overview

Warrick Pharmaceuticals was the generic pharmaceutical division of Schering-Plough Corporation, specializing in respiratory and allergy treatments. The company was best known for its production of generic albuterol inhalers and other respiratory therapies, serving as a strategic vehicle for Schering-Plough to compete in the generic market. Its operations were centered on providing cost-effective alternatives to brand-name metered-dose inhalers and nasal sprays. After Merck & Co. acquired Schering-Plough in 2009, Warrick's assets and product lines were absorbed into Merck's global portfolio. Today, the company no longer operates as an independent entity.

Therapeutic areas: ImmunologyPulmonology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Warrick Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Warrick Pharmaceuticals.

Explore the full profile